Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
KEY TAKEAWAYSNovo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Novo doubles down on next-gen weight loss therapy despite early setback
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Novo Nordisk forecasts slower growth after Wegovy sales double in Q4
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Novo Nordisk stock jumps on Q4 profit beat, strong Wegovy sales and FY25 outlook
Investing.com -- Novo Nordisk 's (CSE: NOVOb ) stock jumped over 3% on Wednesday following a stronger-than-expected ...
Zacks.com on MSN1d
Varonis Systems (VRNS) Q4 Earnings Top Estimates
Varonis Systems (VRNS) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.27 per share a year ago. These ...